According to the latest disclosure, following the completion of the relevant transaction, the pro forma equity value of the merged company, InMed Pharmaceuticals Inc, is expected to reach approximately $421.4 million.

老虎证券2026/05/19 12:15

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

B. Riley raises IMAX target price to $64

格隆汇•2026/10/12 02:39

Cantor Fitzgerald raises Merck target price to $145

格隆汇•2026/10/12 02:35

Saudi-led coalition says it intercepted Houthi ballistic missile toward Khamis Mushait

FXStreet•2026/10/12 02:15

Oppenheimer raises Humana's target price to $475

格隆汇•2026/10/12 02:15